Platelet count doubling after the first cycle of azacitidine therapy predicts eventual response and survival in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukemia but does not add to prognostic utility of the revised IPSS

Reliable clinical or molecular predictors of benefit from azacitidine therapy in patients with myelodysplastic syndromes (MDS) are not defined. Doubling of platelet count at start of second cycle of azacitidine therapy compared to baseline has been associated with achieving response and survival adv...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Br J Haematol
Hlavní autoři: Zeidan, Amer M, Lee, Ju-Whei, Prebet, Thomas, Greenberg, Peter, Sun, Zhuoxin, Juckett, Mark, Smith, Mitchell R, Paietta, Elisabeth, Gabrilove, Janice, Erba, Harry P, Tallman, Martin S., Gore, Steven D.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2014
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4299466/
https://ncbi.nlm.nih.gov/pubmed/24995683
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.13008
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky